A COMPARATIVE STUDY OF FEMALE SEXUAL DYSFUNCTION AMONG WOMEN ON PAROXETINE, SERTRALINE AND ESCITALOPRAM VISITING A RURAL TERTIARY HOSPITAL
Main Article Content
Keywords
Female Sexual Dysfunction; Escitalopram; Paroxetine; Sertraline; SSRI emergent sexual dysfunction.
Abstract
Background
Female Sexual Dysfunction (FSD) is a common clinical issue globally, linked to various medical, gynaecological, psychiatric conditions, and medications. With increased psychotropic use, particularly SSRIs, drug-induced FSD is becoming more prevalent. SSRIs are well-known to impair sexual function, which may reduce adherence, worsen underlying conditions, and negatively impact quality of life and relationships. This study aims to assess the prevalence, incidence, and extent of FSD among SSRI users, along with the specific domains of sexual function affected.
Aim
To study and compare the female sexual dysfunction among patients on Sertraline, Paroxetine and Escitalopram.
Methods
This cross-sectional study included 100 female subjects in remission from primary depressive or anxiety disorders, treated with Paroxetine, Sertraline, or Escitalopram. A semi-structured proforma was used to gather sociodemographic data and premorbid sexual functioning. Female Sexual Dysfunction was assessed using the Female Sexual Function Index (FSFI).
Results
The prevalence of Female Sexual Dysfunction (FSD) was 46.66%, highest with Paroxetine, followed by Sertraline and Escitalopram. All six FSFI domains were affected, with the most common being loss of desire (45%), delay/lack of orgasm (29%), and difficulty with arousal (14%). Paroxetine caused significantly more orgasmic dysfunction compared to Escitalopram. No significant differences were found across other domains or among sociodemographic variables.
Interpretation And Conclusion
The prevalence of drug induced Sexual Dysfunction is of clinical significance which can adversely affect drug compliance and it is an often-underreported side effect. Clinicians must be trained adequately to identify and manage the resultant adverse effects.
References
2. Allahdadi KJ, Tostes RC, Webb RC. Female sexual dysfunction: therapeutic options and experimental challenges. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents). 2009 Oct 1;7(4):260-9.
3. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. J Sex Med. 2007;4:241.
4. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. Geneva: World Health Organization, 1993.
5. Shetageri VN, Bhogale GS, Patil NM, Nayak RB, Chate SS. Sexual dysfunction among females receiving psychotropic medication: a hospital-based cross-sectional study. Indian Journal Psychological Medicine. 2016 Sep;38(5):447-54.
6. Lorenz T, Rullo J, Faubion S. Antidepressant-induced female sexual dysfunction. InMayo Clinic Proceedings 2016 Sep 1 (Vol. 91, No. 9, pp. 1280-1286). Elsevier.
7. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6): 537–544.
8. Montejo-gonzàlez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De LA Gandara J, Derecho J. Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex & Marital Therapy. 1997 Sep 1;23(3):176-94.
9. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266.
10. Hallit S, Haddad C, Hallit R, Akel M, Obeid S, Haddad G, Soufia M, Khansa W, Khoury R, Kheir N, Hallit CA. Validation of the Hamilton anxiety rating scale and state trait anxiety inventory a and B in Arabic among the Lebanese population. Clinical epidemiology and global health. 2020 Dec 1;8(4):1104-9.
11. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of affective disorders. 1988 Jan 1;14(1):61-8.
12. Tung VS, Thong NV, Mai NT, Linh LT, Son DC, Ha TT, Hoa NT, Long NT, Tuan NV. Diagnostic Value in Screening Severe Depression of the Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Beck Depression Inventory Scale, and Zung’s Self-Rating Anxiety Scale Among Patients with Recurrent Depression Disorder. Acta InformaticaMedica.2023;31(4):249.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62.
14. Ma S, Yang J, Yang B, Kang L, Wang P, Zhang N, et al. The Patient Health Questionnaire-9 vs. the Hamilton Rating Scale for Depression in Assessing Major Depressive Disorder. Frontiers in Psychiatry [Internet]. 2021 Nov 4;12.
15. Yusuf M, Abera M, Getnet M, Dawud B. Psychometric properties of Hamilton Depression Rating Scale among people with epilepsy in Jimma University Medical Center, Neurology Clinic, Southwest Ethiopia, 2020: cross-sectional study. BMJ open. 2023 May1;13(5):e070835.
16. Rosen, C. Brown, J. Heiman, S. Leiblum, C. Meston, R. Shabsigh, D. Ferguson, R. D'Agostino R. The Female Sexual Function Index (FSFI): a multidimensional self- report instrument for the assessment of female sexual function. Journal of sex & marital therapy. 2000 Apr 1;26(2):191-208.
17. Ismail SA, Abdel-Azim NE, Saleh MA, Mohamed AA, Yosef AH, Abbas AM. A new grading system for female sexual dysfunction based on the female sexual function index in Egyptian women: a cross-sectional study. African Health Sciences. 2021 Aug 2;21(2):835-41.
18. Maroufizadeh S, Riazi H, Lotfollahi H, Omani-Samani R, Amini P. The 6-item Female Sexual Function Index (FSFI-6): factor structure, reliability, and demographic correlates among infertile women in Iran. Middle East Fertility Society Journal. 2020 Jan;24:1-6.
19. Meston CM, Freihart BK, Handy AB, Kilimnik CD, Rosen RC. Scoring and interpretation of the FSFI: what can be learned from 20 years of use?. The journal of sexual medicine. 2020 Jan;17(1):17-25.
20. Csoka A, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. The journal of sexual medicine. 2008 Jan;5(1):227-33.
21. Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. European neuropsychopharmacology. 2013 Nov1;23(11):1443-51.
22. Jahan MS, Billah SM, Furuya H, Watanabe T. Female sexual dysfunction: facts and factors among gynecology outpatients. Journal of Obstetrics and Gynaecology Research. 2012Jan;38(1):329-35.
23. Erdős C, Kelemen O, Pócs D, Horváth E, Dudás N, Papp A, Paulik E. Female sexual dysfunction in association with sexual history, sexual abuse and satisfaction: A crosssectional study in Hungary. Journal of Clinical Medicine. 2023 Jan 31;12(3):1112.
24. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Mental Health Clinician. 2016 Jul1;6(4):191-6.
25. Roy P, Gupta B, Tripathi A, Nischal A, Dalal PK, Kar SK. Sexual functioning in females with depression in remission receiving escitalopram. The Indian Journal of Medical Research[Internet]. 2019 Dec 1;150(6):606–11.
26. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clinical Pharmacology & Therapeutics.1997 Apr;61(4):476-87.
27. Arlas F, Padin JJ, Rivas MT, Sánchez A. . Sexual dysfunctions induced by serotonin reuptakeinhibitors. Aten Primaria. 2000; 26 6: 389- 94.
28. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).International clinical psychopharmacology. 1994 Mar 1;9:19-26.
29. Corona G, Ricca V, Bandini E, Mannucci E, Lotti F, Boddi V, Rastrelli G, Sforza A, Faravelli C, Forti G, Maggi M. Selective serotonin reuptake inhibitor-induced sexual dysfunction. Thejournal of sexual medicine. 2009 May;6(5):1259-69.
30. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. Journal ofPsychopharmacology. 1998 Jul;12(4):55-S87.
31. Montejo AL, Llorca G, Izquierdo JA. Sexual dysfunction with SSRIs: a comparative analysis. In149th Annual Meeting of the American Psychiatric Association. 1st ed. Washington DC:American Psychiatric Association 1996 May 9 (pp. 266-267).
32. Kennedy SH, Rizvi SJ, Fulton K, Ellis J, Quilty LC, Ravindran L. The sex effects scale: pilot validation in a healthy population. Psychopharmacol Bull. 2010 Jan 1;43(3):15-25.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Sanjana ilavarasu
Senior resident, Department of Psychiatry, Mvj Medical College And Research Institute, Hoskote, Bengaluru, Karnataka, India ,
Dr Abhishek Nagakumar
Assistant professor, Department of Psychiatry, Mvj Medical College And Research Institute, Hoskote, Bengaluru, Karnataka, India ,Email: [email protected]
Dr Kasthuri pandiyan
Professor, Department of Psychiatry, Mvj Medical College And Research Institute, Hoskote, Bengaluru,
